Nektar Therapeutics Securities Fraud Lawsuit Alleges Hidden Enrollment Failures, Adding Legal Risk to Phase 3 Transition

What happened

Nektar Therapeutics faces a securities fraud lawsuit alleging it concealed enrollment protocol failures between February 26, 2025, and December 15, 2025, a period covering key Phase 2b clinical activities for rezpegaldesleukin in atopic dermatitis. According to the DeepValue report, during this timeframe, the company reported positive Phase 2b results but with durability data limited to a responder-enriched cohort, which may relate to the allegations. The report emphasizes Nektar's dependency on a smooth Phase 3 initiation in Q2 2026 and a $300M equity raise to fund operations, with no margin of safety at the current $65 price. This lawsuit introduces legal and regulatory scrutiny that could distract management, delay trials, and complicate the already sensitive financing environment. If proven, the allegations might undermine investor confidence and validate concerns about operational transparency, heightening risks in an already binary investment case.

Implication

The lawsuit adds a new dimension of risk by potentially diverting management focus and resources from critical Phase 3 preparation and enrollment activities. If allegations of hiding enrollment failures hold, it could lead to regulatory penalties, data integrity questions, and eroded trust with partners, impacting Nektar's ability to secure non-dilutive capital. Market sentiment may deteriorate, making the announced $300M equity raise more challenging to complete on favorable terms, thus increasing dilution pressure. Investors should closely monitor lawsuit developments and any disclosures about trial conduct, as adverse outcomes could force Phase 3 delays beyond Q2 2026, aligning with the bear case scenario. Ultimately, this elevates the probability of operational setbacks and financing stress, suggesting a re-assessment of entry points only after legal clarity and verifiable Phase 3 progress.

Thesis delta

The investment thesis shifts from primarily monitoring clinical execution and financing to incorporating significant legal and reputational risks that could derail Phase 3 timelines. The 'WAIT' rating is strengthened, as the lawsuit adds uncertainty to the already fragile funding-sensitive model, potentially pushing the attractive entry below $50 if legal issues escalate. Investors should now prioritize resolving lawsuit uncertainties alongside the original checkpoints of Phase 3 start and raise completion before considering a position.